Reference number : GC-2017-Q3-00565, amendment number : , agreement type : G, recipient legal name : Loewen, Christopher (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Salmonella infections represent a significant public health concern and disease burden. Significant sources of_x000D_
infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of_x000D_
Salmonella infections in poultry products is one means to reduce human infections. While advances have been_x000D_
made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure_x000D_
on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities._x000D_
NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that_x000D_
could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest_x000D_
poultry production facilities. Currently, novel Salmonella-specific antibodies (NBXs) have been generated and_x000D_
tested for their efficacy using in vitro and in vivo methods. This proposal relies on the expertise of Dr. Chris_x000D_
Loewen and his laboratory in the fields of yeast genetics, protein production and biochemistry. This work will_x000D_
generate yeast strains that can produce and hopefully improve NBXs efficacy in blocking Salmonella infection_x000D_
in chickens. Additionally, we will develop stable pro-biotic yeast strains expressing NBXs for direct inclusion_x000D_
in chicken feed. Our approach will combine promoters of chicken gastrointestinal health with pathogen specific_x000D_
NBXs that inhibit key virulence pathways. The following steps will be taken to determine the synergistic_x000D_
efficacy of our conjugate approach: (1) NBXs will be engineered to contain sites for glycosylation in yeast. (2)_x000D_
NBXs will be expressed as soluble and membrane bound variants, or both, in Sacchyomyces cerevisiae and_x000D_
Pichia pastoris. (3) Soluble NBXs and NBX-producing yeast will be tested in vitro for improved activity_x000D_
against Salmonella. (4) The efficacy of NBXs against Salmonella infection will be tested in vivo in chickens._x000D_
The development of a Salmonella-selective and highly effective antibody would benefit Canadian and world_x000D_
populations by reducing human infection and illness, loss of life, and costs of treatment. The revenue generated_x000D_
by NovoBind in delivering this product would also be an economic boost to Canada., program purpose french : Salmonella infections represent a significant public health concern and disease burden. Significant sources of_x000D_
infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of_x000D_
Salmonella infections in poultry products is one means to reduce human infections. While advances have been_x000D_
made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure_x000D_
on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities._x000D_
NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that_x000D_
could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest_x000D_
poultry production facilities. Currently, novel Salmonella-specific antibodies (NBXs) have been generated and_x000D_
tested for their efficacy using in vitro and in vivo methods. This proposal relies on the expertise of Dr. Chris_x000D_
Loewen and his laboratory in the fields of yeast genetics, protein production and biochemistry. This work will_x000D_
generate yeast strains that can produce and hopefully improve NBXs efficacy in blocking Salmonella infection_x000D_
in chickens. Additionally, we will develop stable pro-biotic yeast strains expressing NBXs for direct inclusion_x000D_
in chicken feed. Our approach will combine promoters of chicken gastrointestinal health with pathogen specific_x000D_
NBXs that inhibit key virulence pathways. The following steps will be taken to determine the synergistic_x000D_
efficacy of our conjugate approach: (1) NBXs will be engineered to contain sites for glycosylation in yeast. (2)_x000D_
NBXs will be expressed as soluble and membrane bound variants, or both, in Sacchyomyces cerevisiae and_x000D_
Pichia pastoris. (3) Soluble NBXs and NBX-producing yeast will be tested in vitro for improved activity_x000D_
against Salmonella. (4) The efficacy of NBXs against Salmonella infection will be tested in vivo in chickens._x000D_
The development of a Salmonella-selective and highly effective antibody would benefit Canadian and world_x000D_
populations by reducing human infection and illness, loss of life, and costs of treatment. The revenue generated_x000D_
by NovoBind in delivering this product would also be an economic boost to Canada., agreement title english : Generation of Yeast Produced Multifunctional Antibody-Based Therapeutics Against Salmonella Gastroenteritis, agreement title french : Generation of Yeast Produced Multifunctional Antibody-Based Therapeutics Against Salmonella Gastroenteritis, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-10-18, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada